CSRGPS

CSRGPS predicts survival in silico.

“It stratified patients into distinct prognostic groups exhibiting differences in survival, clinical features, biological functions, and the tumor microenvironment”

In silicoin glioma patients

A machine learning-defined cellular senescence signature systematically enhances prognostication and guides immunotherapy strategies for the treatment of gliomas

NPJ precision oncology·7 Jan 2026